Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Dec;81(8):1371–1377. doi: 10.1038/sj.bjc.6693403

Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas

S Balesaria 1, C Brock 1, M Bower 2, J Clark 3, S K Nicholson 1, P Lewis 4, S de Sanctis 4, H Evans 1, D Peterson 5, N Mendoza 5, M G Glaser 1, E S Newlands 1, R A Fisher 1
PMCID: PMC2362970  PMID: 10604735

Abstract

Loss of heterozygosity (LOH) for chromosome 10 is the most frequent genetic abnormality observed in high-grade gliomas. We have used fluorescent microsatellite markers to examine a series of 83 patients, 34 with anaplastic astrocytoma (grade 3) and 49 with glioblastoma multiforme (grade 4), for LOH of chromosome 10. Genotype analysis revealed LOH for all informative chromosome 10 markers in 12 (35%) of patients with grade 3 and 29 (59%) grade 4 tumours respectively, while partial LOH was found in a further eight (24%) grade 3 and ten (20%) grade 4 tumours. Partial LOH, was confined to the long arm (10q) in six and the short arm (10p) in three cases, while alleles from both arms were lost in four cases. Five tumours (one grade 3 and four grade 4) showed heterogeneity with respect to loss at different loci. There was a correlation between any chromosome 10 loss and poorer performance status at presentation (χ2P = 0.005) and with increasing age at diagnosis (Mann–Whitney U-test P = 0.034) but not with tumour grade (χ2P = 0.051). A Cox multivariate model for survival duration identified age (proportional hazards (PH), P = 0.004), grade (PH, P = 0.012) and any loss of chromosome 10 (PH, P = 0.009) as the only independent prognostic variables. Specifically, LOH for chromosome 10 was able to identify a subgroup of patients with grade 3 tumours who had a significantly shorter survival time. We conclude that LOH for chromosome 10 is an independent, adverse prognostic variable in high-grade glioma. © 1999 Cancer Research Campaign

Keywords: glioma, brain tumour, loss of heterozygosity, microsatellite

Full Text

The Full Text of this article is available as a PDF (109.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker F. G., 2nd, Davis R. L., Chang S. M., Prados M. D. Necrosis as a prognostic factor in glioblastoma multiforme. Cancer. 1996 Mar 15;77(6):1161–1166. doi: 10.1002/(sici)1097-0142(19960315)77:6<1161::aid-cncr24>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  2. Bigner S. H., Mark J., Bigner D. D. Cytogenetics of human brain tumors. Cancer Genet Cytogenet. 1990 Jul 15;47(2):141–154. doi: 10.1016/0165-4608(90)90024-5. [DOI] [PubMed] [Google Scholar]
  3. Boström J., Cobbers J. M., Wolter M., Tabatabai G., Weber R. G., Lichter P., Collins V. P., Reifenberger G. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res. 1998 Jan 1;58(1):29–33. [PubMed] [Google Scholar]
  4. Campomenosi P., Ottaggio L., Moro F., Urbini S., Bogliolo M., Zunino A., Camoriano A., Inga A., Gentile S. L., Pellegata N. S. Study on aneuploidy and p53 mutations in astrocytomas. Cancer Genet Cytogenet. 1996 Jun;88(2):95–102. doi: 10.1016/0165-4608(95)00359-2. [DOI] [PubMed] [Google Scholar]
  5. Chang C. H., Horton J., Schoenfeld D., Salazer O., Perez-Tamayo R., Kramer S., Weinstein A., Nelson J. S., Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983 Sep 15;52(6):997–1007. doi: 10.1002/1097-0142(19830915)52:6<997::aid-cncr2820520612>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  6. Chernova O. B., Somerville R. P., Cowell J. K. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene. 1998 Dec 3;17(22):2873–2881. doi: 10.1038/sj.onc.1202481. [DOI] [PubMed] [Google Scholar]
  7. Collins V. P. Gene amplification in human gliomas. Glia. 1995 Nov;15(3):289–296. doi: 10.1002/glia.440150309. [DOI] [PubMed] [Google Scholar]
  8. Cunningham J. M., Kimmel D. W., Scheithauer B. W., O'Fallon J. R., Novotny P. J., Jenkins R. B. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. J Neurosurg. 1997 Jan;86(1):121–130. doi: 10.3171/jns.1997.86.1.0121. [DOI] [PubMed] [Google Scholar]
  9. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer. 1988 Nov 15;62(10):2152–2165. doi: 10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  10. Fisher R. A., Paradinas F. J., Soteriou B. A., Foskett M., Newlands E. S. Diploid hydatidiform moles with fetal red blood cells in molar villi. 2--Genetics. J Pathol. 1997 Feb;181(2):189–195. doi: 10.1002/(SICI)1096-9896(199702)181:2<189::AID-PATH760>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  11. Fults D., Pedone C. A., Thompson G. E., Uchiyama C. M., Gumpper K. L., Iliev D., Vinson V. L., Tavtigian S. V., Perry W. L., 3rd Microsatellite deletion mapping on chromosome 10q and mutation analysis of MMAC1, FAS, and MXI1 in human glioblastoma multiforme. Int J Oncol. 1998 Apr;12(4):905–910. doi: 10.3892/ijo.12.4.905. [DOI] [PubMed] [Google Scholar]
  12. Ganju V., Jenkins R. B., O'Fallon J. R., Scheithauer B. W., Ransom D. T., Katzmann J. A., Kimmel D. W. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer. 1994 Aug 1;74(3):920–927. doi: 10.1002/1097-0142(19940801)74:3<920::aid-cncr2820740320>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  13. Ichimura K., Schmidt E. E., Miyakawa A., Goike H. M., Collins V. P. Distinct patterns of deletion on 10p and 10q suggest involvement of multiple tumor suppressor genes in the development of astrocytic gliomas of different malignancy grades. Genes Chromosomes Cancer. 1998 May;22(1):9–15. doi: 10.1002/(sici)1098-2264(199805)22:1<9::aid-gcc2>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  14. Jen J., Harper J. W., Bigner S. H., Bigner D. D., Papadopoulos N., Markowitz S., Willson J. K., Kinzler K. W., Vogelstein B. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 1994 Dec 15;54(24):6353–6358. [PubMed] [Google Scholar]
  15. Kon H., Sonoda Y., Kumabe T., Yoshimoto T., Sekiya T., Murakami Y. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas. Oncogene. 1998 Jan 15;16(2):257–263. doi: 10.1038/sj.onc.1201488. [DOI] [PubMed] [Google Scholar]
  16. Korkolopoulou P., Christodoulou P., Kouzelis K., Hadjiyannakis M., Priftis A., Stamoulis G., Seretis A., Thomas-Tsagli E. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 1997;75(9):1269–1278. doi: 10.1038/bjc.1997.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Krouwer H. G., Davis R. L., Silver P., Prados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 1991 Mar;74(3):399–406. doi: 10.3171/jns.1991.74.3.0399. [DOI] [PubMed] [Google Scholar]
  18. Leenstra S., Oskam N. T., Bijleveld E. H., Bosch D. A., Troost D., Hulsebos T. J. Genetic sub-types of human malignant astrocytoma correlate with survival. Int J Cancer. 1998 Apr 17;79(2):159–165. doi: 10.1002/(sici)1097-0215(19980417)79:2<159::aid-ijc11>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  19. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., Puc J., Miliaresis C., Rodgers L., McCombie R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997 Mar 28;275(5308):1943–1947. doi: 10.1126/science.275.5308.1943. [DOI] [PubMed] [Google Scholar]
  20. Lin H., Bondy M. L., Langford L. A., Hess K. R., Delclos G. L., Wu X., Chan W., Pershouse M. A., Yung W. K., Steck P. A. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998 Oct;4(10):2447–2454. [PubMed] [Google Scholar]
  21. Louis D. N., Gusella J. F. A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet. 1995 Oct;11(10):412–415. doi: 10.1016/s0168-9525(00)89125-8. [DOI] [PubMed] [Google Scholar]
  22. Mollenhauer J., Wiemann S., Scheurlen W., Korn B., Hayashi Y., Wilgenbus K. K., von Deimling A., Poustka A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nat Genet. 1997 Sep;17(1):32–39. doi: 10.1038/ng0997-32. [DOI] [PubMed] [Google Scholar]
  23. Newlands E. S., O'Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996 Dec;32A(13):2236–2241. doi: 10.1016/s0959-8049(96)00258-4. [DOI] [PubMed] [Google Scholar]
  24. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Rainov N. G., Dobberstein K. U., Bahn H., Holzhausen H. J., Lautenschläger C., Heidecke V., Burkert W. Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J Neurooncol. 1997 Oct;35(1):13–28. doi: 10.1023/a:1005841520514. [DOI] [PubMed] [Google Scholar]
  26. Rasheed B. K., McLendon R. E., Friedman H. S., Friedman A. H., Fuchs H. E., Bigner D. D., Bigner S. H. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene. 1995 Jun 1;10(11):2243–2246. [PubMed] [Google Scholar]
  27. Rasheed B. K., Stenzel T. T., McLendon R. E., Parsons R., Friedman A. H., Friedman H. S., Bigner D. D., Bigner S. H. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997 Oct 1;57(19):4187–4190. [PubMed] [Google Scholar]
  28. Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., Langford L. A., Baumgard M. L., Hattier T., Davis T. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997 Apr;15(4):356–362. doi: 10.1038/ng0497-356. [DOI] [PubMed] [Google Scholar]
  29. Voesten A. M., Bijleveld E. H., Westerveld A., Hulsebos T. J. Fine mapping of a region of common deletion on chromosome arm 10p in human glioma. Genes Chromosomes Cancer. 1997 Oct;20(2):167–172. [PubMed] [Google Scholar]
  30. Waha A., Baumann A., Wolf H. K., Fimmers R., Neumann J., Kindermann D., Astrahantseff K., Blümcke I., von Deimling A., Schlegel U. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. J Neurosurg. 1996 Oct;85(4):634–641. doi: 10.3171/jns.1996.85.4.0634. [DOI] [PubMed] [Google Scholar]
  31. Zhu A., Shaeffer J., Leslie S., Kolm P., El-Mahdi A. M. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809–815. doi: 10.1016/0360-3016(95)02184-1. [DOI] [PubMed] [Google Scholar]
  32. von Deimling A., Louis D. N., Wiestler O. D. Molecular pathways in the formation of gliomas. Glia. 1995 Nov;15(3):328–338. doi: 10.1002/glia.440150312. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES